Estimating the response and economic burden of rheumatoid arthritis patients treated with biologic disease-modifying antirheumatic drugs in Taiwan using the National Health Insurance Research Database (NHIRD)-Reference-Cited by-同舟云学术

Estimating the response and economic burden of rheumatoid arthritis patients treated with biologic disease-modifying antirheumatic drugs in Taiwan using the National Health Insurance Research Database (NHIRD)

Published:2018-04-06 Issue:4 Volume:13 Page:e0193489
ISSN:1932-6203
Container-title:PLOS ONE
language:en
Short-container-title:PLoS ONE

Author:

Shi Qiang,Li Ko-Jen,Treuer Tamas,Wang Bruce C. M.,Gaich Carol L.,Lee Chien-Hsun,Wu Wen-Shuo,Furnback Wesley,Tang Chao-Hsiun

Funder

Eli Lilly & Co

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference36 articles.

1. The pathogenesis of rheumatoid arthritis;I McInnes;New England Journal of Medicine,2011

2. Global Health Epidemiology Reference Group (GHERG). Prevalence of rheumatoid arthritis in low- and middle-income countries: A systematic review and analysis;I Rudan;J Glob Health,2015

3. Rheumatoid arthritis prevalence, incidence, and mortality rates: a nationwide population study in Taiwan;CF Kuo;Rheumatol Int,2013

4. Nationwide population-based epidemiologic study of rheumatoid arthritis in Taiwan;CH Lai;Clin Exp Rheumatol,2012

5. Rheumatoid arthritis;DL Scott;Lancet,2010

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Physicians’ and patients’ perception of biosimilars and factors affecting biosimilar prescribing in selected Asian Countries: a survey study;Expert Opinion on Biological Therapy;2024-09-05

2. Healthcare resource utilisation and economic burden of patients with adequate and inadequate responses to biological and targeted synthetic disease-modifying antirheumatic drugs for rheumatoid arthritis in Japan;Modern Rheumatology;2023-11-09

4. Clinical outcomes and prognostic factors of bronchiectasis rheumatoid overlap syndrome: A multi-institution cohort study;Frontiers in Medicine;2022-10-13

5. Patient-reported outcomes of upadacitinib versus abatacept in patients with rheumatoid arthritis and an inadequate response to biologic disease-modifying antirheumatic drugs: 12- and 24-week results of a phase 3 trial;Arthritis Research & Therapy;2022-06-24